Medindia11h
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Melanoma
PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...
News-Medical.Net on MSN10d
Melanoma cells use stealth strategy to survive targeted therapy
Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...
The Manila Times13h
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
Beating the clock: Melanoma starts evading treatment within hours; here's how to stop it
Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.
Innovent Receives NMPA Breakthrough Therapy Designation For IBI363 (PD-1/IL-2Α-Bias Bispecific Antibody Fusion Protein) In Melanoma
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
Novel oral drug therapy combination shows promise for advanced melanoma patients
A research team led by Sheri Holmen, Ph.D., investigator at Huntsman Cancer Institute and professor in the Department of ...
Technology Networks7d
Combination Drug Therapy Shows Promise for Treating Melanoma
Researchers are testing a new combination drug therapy that could both treat and prevent melanoma metastasis, or spreading ...
EurekAlert!11d
Beating the clock: Melanoma starts evading treatment within hours – here’s how to stop it
researchers mapped the molecular shifts in melanoma cells over minutes, hours, and days of BRAF inhibitor treatment. “We found that while the BRAF-ERK signaling pathway was quickly and durably ...
BioWorld27d
Combination therapy overcomes treatment resistance in melanoma
Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation through pathways involved in focal ...